Patient Population (n=71)
- Female patients age ≥18 years
- Recurrent or advanced endometrial cancer that had progressed on or following treatment with a platinum-containing regimen
- Tumors that were mismatch repair deficient as determined by IHC testing. The dMMR tumor status was retrospectively confirmed using the VENTANA MMR RxDx Panel assay
500 mg every 3 weeks
for 4 doses, followed by
1000 mg every 6 weeks*
Key Efficacy Endpoints†
- Overall response rate (ORR)
- Duration of response (DOR)
ECOG=Eastern Cooperative Oncology Group; FIGO=International Federation of Gynecology and Obstetrics.
Learn about response with
Learn about the safety and
tolerability profile of JEMPERLI.
Find out how to dose and